GO:0061909 autophagosome-lysosome fusion: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061909 autophagosome-lysosome fusion is the biological process in which double-membraned autophagosomes fuse with lysosomes (or yeast vacuoles), delivering cytoplasmic cargo for degradation.
• Fusion is the terminal and rate-limiting step of autophagic flux; blocking it causes autophagosome accumulation and is a common off-target effect of drugs such as chloroquine and bafilomycin A1.
• The core machinery includes SNARE proteins (STX17, SNAP29, VAMP8), RAB7A, HOPS tethering complex, and lysosomal membrane proteins such as LAMP2.
• Regulation involves RAB7A ubiquitylation, V-ATPase-dependent acidification, and Ca-P60A/SERCA-dependent calcium signaling.
• Defective fusion is linked to periodontitis, septic heart injury, vascular smooth muscle cell senescence, and impaired autophagic flux in multiple disease models.
• Research methods include fluorescent reporters (GFP-LC3, RFP-LC3), electron microscopy, live-cell imaging, and CRISPR-based knockout or knock-in models.
Description
Autophagosome-lysosome fusion (GO:0061909) is the final and essential step of macroautophagy, during which double-membraned autophagosomes carrying cytoplasmic cargo fuse with lysosomes (or vacuoles in yeast) to form autolysosomes. This fusion event delivers the inner autophagosomal membrane and its contents into an acidic, hydrolase-rich environment, enabling the degradation and recycling of proteins, lipids, and organelles. Without fusion, autophagosomes accumulate and autophagic flux is blocked, a state observed in many pathological conditions. The process is highly conserved and requires coordinated action of SNARE proteins, RAB GTPases, tethering complexes, and lysosomal membrane proteins. Researchers study GO:0061909 to understand how cells maintain proteostasis, respond to stress, and defend against pathogens, and to identify therapeutic targets for diseases ranging from neurodegeneration to cancer.
autophagosome-lysosome fusion At A Glance
| GO ID | GO:0061909 |
|---|---|
| GO term | autophagosome-lysosome fusion |
| Ontology | biological_process |
| Synonym | autophagosome fusion; autophagosome-vacuole fusion |
| Major function | Fusion of autophagosomes with lysosomes/vacuoles to deliver cytoplasmic cargo for degradation |
| Cellular location | Cytoplasm; autophagosome and lysosome membranes |
| Key machinery | SNARE proteins (STX17, SNAP29, VAMP8), RAB7A, HOPS complex, LAMP2 |
| Related process | Macroautophagy; autophagic flux; endolysosomal degradation |
What Is GO:0061909?
GO:0061909 autophagosome-lysosome fusion is defined as the process in which autophagosomes, double-membraned vesicles containing cytoplasmic material, fuse with a vacuole (in yeast) or a lysosome (in mammals and insects). In yeast, inner membrane-bounded structures called autophagic bodies appear in the vacuole. Fusion provides an acidic environment and digestive function to the interior of the autophagosome, allowing cargo degradation.
Why Is autophagosome-lysosome fusion Important in Cell Biology?
Autophagosome-lysosome fusion is the committing step of autophagic degradation; without it, autophagosomes cannot deliver their cargo to acidic hydrolases, leading to impaired proteostasis and cellular stress. Defects in this process are implicated in infectious diseases, inflammatory conditions, cardiovascular injury, and aging-related pathologies. Moreover, many pharmacological agents, including chloroquine and bafilomycin A1, inhibit autophagy by blocking fusion, making it a critical consideration in drug development and autophagy research.
• Terminal and rate-limiting step of autophagic flux; its failure causes autophagosome accumulation.
• Essential for degradation of damaged organelles, protein aggregates, and intracellular pathogens.
• Target of autophagy inhibitors such as chloroquine and bafilomycin A1, widely used in research and therapy.
• Dysregulated in periodontitis via USP4-mediated RAB7A ubiquitylation.
• Protective role in septic heart injury through LAMP2-FLOT2 interaction.
• Implicated in vascular smooth muscle cell senescence and metformin response.
• Requires precise SNARE complex assembly; mutations or imbalances impair fusion.
• Serves as a biomarker of autophagic flux in cancer, neurodegeneration, and metabolic diseases.
What Happens During autophagosome-lysosome fusion?
Autophagosome maturation and transport
In simple terms: The autophagosome must first mature and move close to the lysosome before they can fuse.
After formation, autophagosomes undergo maturation, acquiring proteins and lipids that prepare them for fusion. They are transported along microtubules toward lysosomes, a step regulated by RAB7A and its effectors. Defects in transport or maturation prevent fusion and cause autophagosome accumulation.
Tethering and docking
In simple terms: Tethering proteins physically link the autophagosome and lysosome together before fusion.
The HOPS complex and RAB7A mediate tethering of autophagosomes to lysosomes. RAB7A recruits HOPS, which interacts with SNARE proteins to promote membrane proximity. Ubiquitylation of RAB7A by USP4 depletion impairs this tethering, reducing fusion efficiency.
SNARE-mediated membrane fusion
In simple terms: SNARE proteins act like molecular zippers that pull the two membranes together for fusion.
The autophagosomal SNARE STX17 forms a complex with SNAP29 and the lysosomal SNARE VAMP8, catalyzing membrane fusion. This SNARE complex is essential; knockdown or mutation of these proteins blocks autophagosome-lysosome fusion and autophagic flux.
Acidification and cargo degradation
In simple terms: After fusion, the acidic environment of the lysosome breaks down the cargo.
Fusion delivers autophagosomal contents into the acidic lysosomal lumen, where hydrolases degrade them. V-ATPase-dependent acidification is required; bafilomycin A1 inhibits both acidification and fusion, disrupting autophagic flux. LAMP2 and FLOT2 interaction enhances fusion and protects against septic heart injury.
Regulation by calcium and signaling
In simple terms: Calcium signals and cellular stress pathways can speed up or slow down fusion.
Ca-P60A/SERCA-dependent calcium signaling regulates autophagosome-lysosome fusion; bafilomycin A1 disrupts this pathway. Metformin promotes autophagic flux by enhancing fusion in vascular smooth muscle cells. These regulatory inputs allow cells to adapt autophagy to metabolic and stress conditions.
Key Genes Involved in GO:0061909 autophagosome-lysosome fusion
The following genes and proteins are central to autophagosome-lysosome fusion, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| STX17 | Autophagosomal SNARE mediating fusion | Knockout blocks fusion; target for flux studies |
| SNAP29 | SNARE complex component | Mutations impair fusion; used in reconstitution assays |
| VAMP8 | Lysosomal SNARE | Knockdown inhibits fusion; marker of lysosomal competence |
| RAB7A | GTPase regulating tethering and fusion | Ubiquitylation impairs fusion in periodontitis |
| LAMP2 | Lysosomal membrane protein | Interaction with FLOT2 enhances fusion in septic heart |
| FLOT2 | Membrane raft protein | Partners with LAMP2 to promote fusion |
| USP4 | Deubiquitylase regulating RAB7A stability | Depletion drives RAB7A ubiquitylation and fusion defects |
| V-ATPase | Proton pump acidifying lysosomes | Target of bafilomycin A1; required for fusion |
| SERCA (Ca-P60A) | Calcium pump regulating fusion | Inhibited by bafilomycin A1; modulates fusion |
| HOPS complex | Tethering complex | Mediates RAB7A-dependent docking |
| LC3 | Autophagosome marker | Used to monitor fusion and flux |
| GABARAP | Autophagosome membrane protein | Participates in fusion machinery |
| ATG14 | Autophagy initiation factor | Indirectly affects fusion competence |
| PLEKHM1 | Adaptor linking RAB7A to HOPS | Regulates fusion efficiency |
| EPG5 | Tethering factor | Mutations cause autophagosome accumulation |
| SNARE complex | Core fusion machinery | Target for functional studies |
| mTOR | Kinase regulating autophagy initiation | Indirectly influences fusion via autophagosome supply |
| TFEB | Transcription factor controlling lysosomal biogenesis | Overexpression enhances fusion capacity |
How Is autophagosome-lysosome fusion Regulated?
Autophagosome-lysosome fusion is regulated at multiple levels. RAB7A activity is controlled by ubiquitylation; USP4 depletion increases RAB7A ubiquitylation and impairs fusion. Calcium signaling via SERCA and V-ATPase-dependent acidification are required, and bafilomycin A1 disrupts both. Metformin promotes fusion in vascular smooth muscle cells, linking metabolic signaling to autophagic flux. LAMP2-FLOT2 interaction enhances fusion under inflammatory conditions. These regulatory mechanisms ensure fusion is responsive to cellular stress and nutrient status.
autophagosome-lysosome fusion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| USP4 | Periodontitis | USP4 knockout in periodontal cells; RAB7A ubiquitylation assays |
| LAMP2 | Septic heart injury | LAMP2 knockout or knock-in mice; ILC2 co-culture |
| FLOT2 | Septic heart injury | FLOT2 overexpression in cardiomyocytes |
| RAB7A | Periodontitis; fusion defects | RAB7A point mutant (ubiquitylation-resistant) knock-in |
| SERCA | Drug-induced fusion block | SERCA overexpression or point mutation |
Periodontitis
USP4 depletion-driven RAB7A ubiquitylation impairs autophagosome-lysosome fusion and aggravates periodontitis, suggesting that fusion defects contribute to inflammatory bone loss.
Septic heart injury
LAMP2-FLOT2 interaction enhances autophagosome-lysosome fusion to protect the septic heart in response to ILC2, indicating a protective role for fusion in cardiac inflammation.
Vascular senescence
Metformin suppresses vascular smooth muscle cell senescence by promoting autophagic flux, which depends on efficient autophagosome-lysosome fusion.
Drug-induced autophagy inhibition
Chloroquine and bafilomycin A1 inhibit autophagic flux by decreasing autophagosome-lysosome fusion, a mechanism relevant to their clinical and experimental use.
From autophagosome-lysosome fusion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate autophagosome-lysosome fusion? | CRISPR knockout of gene X in HeLa or HEK293T cells |
| Does a point mutation in RAB7A affect fusion? | RAB7A point-mutation knock-in via CRISPR |
| Does LAMP2-FLOT2 interaction enhance fusion? | LAMP2 tagged knock-in or overexpression |
| Does USP4 depletion impair fusion? | USP4 knockout cells; RAB7A ubiquitylation analysis |
| Does metformin promote fusion? | Vascular smooth muscle cells treated with metformin; LC3 flux assay |
| Does bafilomycin A1 block fusion? | Wild-type cells treated with bafilomycin A1; imaging |
How to Study the autophagosome-lysosome fusion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GFP-LC3/RFP-LC3 imaging | Autophagosome-lysosome co-localization | Fusion efficiency in live cells |
| Electron microscopy | Ultrastructure of autophagosomes and autolysosomes | Confirming fusion events |
| LC3 turnover assay | Autophagic flux | Drug effects on fusion |
| Immunoblotting | Protein levels of SNAREs, RAB7A, LAMP2 | Knockout validation |
| Proximity ligation assay | SNARE complex formation | Fusion machinery assembly |
| Calcium imaging | SERCA-dependent calcium signals | Regulation of fusion |
| Ubiquitylation assays | RAB7A modification | USP4 function in fusion |
| Transcriptomics | Lysosomal and autophagy gene expression | TFEB pathway analysis |
Fluorescent reporters and live-cell imaging
GFP-LC3 and RFP-LC3 reporters allow monitoring of autophagosome formation and fusion with lysosomes. Co-localization of LC3 with lysosomal markers such as LAMP2 indicates fusion.
Electron microscopy
Transmission electron microscopy visualizes autophagosomes and autolysosomes at ultrastructural resolution, confirming fusion events and autophagic body accumulation in yeast.
Autophagic flux assays
LC3 turnover assays in the presence and absence of lysosomal inhibitors (e.g., chloroquine, bafilomycin A1) measure fusion-dependent degradation.
Proteomics and interactomics
Mass spectrometry identifies SNARE complexes, RAB7A effectors, and post-translational modifications such as ubiquitylation that regulate fusion.
How CRISPR Can Be Used to Study GO:0061909 autophagosome-lysosome fusion
Knockout
CRISPR knockout of STX17, SNAP29, VAMP8, or RAB7A abolishes autophagosome-lysosome fusion, providing causal evidence for their essential roles.
Point Mutation
Point mutations in RAB7A that prevent ubiquitylation can be introduced to test whether modification is required for fusion. Similarly, mutations in SNARE domains can disrupt complex formation.
Knock-in
Tagged knock-in of LAMP2 or FLOT2 allows tracking of endogenous proteins and assessment of their interaction in fusion. Knock-in of fluorescent LC3 enables real-time flux monitoring.
Overexpression
Overexpression of TFEB or LAMP2 enhances lysosomal biogenesis and fusion capacity, useful for rescue experiments. Overexpression of dominant-negative RAB7A blocks fusion.
How EDITGENE Supports autophagosome-lysosome fusion Research
Researchers studying autophagosome-lysosome fusion-related genes often need to determine whether a candidate gene is causally involved in fusion, how mutations affect SNARE complex assembly, and whether restoring fusion rescues disease phenotypes. EDITGENE provides CRISPR-based cell models and screening services to address these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for autophagosome-lysosome fusion research.
Frequently Asked Questions About autophagosome-lysosome fusion
What is autophagosome-lysosome fusion?
It is the process by which autophagosomes fuse with lysosomes to deliver cytoplasmic cargo for degradation, defined as GO:0061909.
What genes are involved in autophagosome-lysosome fusion?
Key genes include STX17, SNAP29, VAMP8, RAB7A, LAMP2, FLOT2, USP4, and the HOPS complex components.
How is autophagosome-lysosome fusion regulated?
It is regulated by RAB7A ubiquitylation, calcium signaling via SERCA, V-ATPase-dependent acidification, and proteins such as LAMP2 and FLOT2.
What drugs inhibit autophagosome-lysosome fusion?
Chloroquine and bafilomycin A1 inhibit fusion, blocking autophagic flux.
What diseases are linked to defective autophagosome-lysosome fusion?
Periodontitis, septic heart injury, and vascular senescence have been associated with fusion defects.
How can I measure autophagosome-lysosome fusion in the lab?
Use GFP-LC3/RFP-LC3 imaging, LC3 turnover assays, electron microscopy, and SNARE complex analysis.
What is the role of SNARE proteins in autophagosome-lysosome fusion?
STX17, SNAP29, and VAMP8 form a SNARE complex that catalyzes membrane fusion.
How does RAB7A regulate autophagosome-lysosome fusion?
RAB7A mediates tethering and docking; its ubiquitylation impairs fusion.
Can CRISPR be used to study autophagosome-lysosome fusion?
Yes, CRISPR knockout, knock-in, and point mutation models are widely used to dissect fusion mechanisms.
What is the difference between autophagosome-lysosome fusion and autophagic flux?
Fusion is a step within autophagic flux; flux encompasses the entire process from autophagosome formation to degradation.
Conclusion
Autophagosome-lysosome fusion (GO:0061909) is a central biological process that determines the efficiency of autophagic degradation. Its molecular machinery, including SNARE proteins, RAB7A, and lysosomal membrane proteins, is tightly regulated and frequently dysregulated in disease. Continued research using CRISPR models and advanced imaging will clarify how fusion is controlled and how it can be targeted therapeutically.
References
- 1. Lőrincz P et al.. 2020. Autophagosome-Lysosome Fusion.. J Mol Biol 432(8):2462-2482 PMID: 31682838
- 2. Tian X et al.. 2021. New insights regarding SNARE proteins in autophagosome-lysosome fusion.. Autophagy 17(10):2680-2688 PMID: 32924745
- 3. Mauthe M et al.. 2018. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion.. Autophagy 14(8):1435-1455 PMID: 29940786
- 4. Kang S et al.. 2025. USP4 depletion-driven RAB7A ubiquitylation impairs autophagosome-lysosome fusion and aggravates periodontitis.. Autophagy 21(4):771-788 PMID: 39663592
- 5. Mauvezin C et al.. 2015. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion.. Autophagy 11(8):1437-8 PMID: 26156798
- 6. Liu S et al.. 2025. Spatio-temporal processes in autophagosome-lysosome fusion.. Med Rev (2021) 5(4):297-317 PMID: 40838105
- 7. Tai S et al.. 2022. Metformin suppresses vascular smooth muscle cell senescence by promoting autophagic flux.. J Adv Res 41:205-218 PMID: 36328749
- 8. Shao R et al.. 2025. LAMP2-FLOT2 interaction enhances autophagosome-lysosome fusion to protect the septic heart in response to ILC2.. Autophagy 21(9):1888-1910 PMID: 40066518
